ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
08 December 2023 - 3:20AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of renal and inflammatory diseases, announces
publication of an article in the peer-reviewed journal, Alternative
Therapies, demonstrating that plasma NLRP3 inflammasomes and their
resulting proinflammatory cytokines are significantly elevated in
early-stage DKD and that levels progressively increase as kidney
function worsens.
In the paper titled, “Correlation Between Plasma
NLRP3, IL-1β, and IL-18 and Diabetic Nephropathy in Patients With
Type 2 Diabetes,” the authors evaluated the plasma of 152 patients
with type 2 diabetes and DKD stratified by stage of disease (stages
1-5) and 30 patients with type 2 diabetes without kidney disease
who serve as controls. Following are key findings reported in the
paper:
- Plasma levels of NLRP3 and
proinflammatory cytokines, IL-1β, and IL-18, were significantly
higher than controls in patients in each of the 5 stages of DKD,
with progressively higher levels as kidney disease progressed
(p<0.01).
- NLRP3, IL-1β, and IL-18 levels
positively correlated with DKD stage (p= 0.01), based on the
Spearman correlation analysis.
- These data are consistent with other
studies demonstrating that inflammation has an important role in
the development and progression of DKD.
To read the article, Click Here.
“The research published in Alternative Therapies
reinforces the role of inflammasome-driven inflammation in
development and progression of DKD, the leading cause of end-stage
kidney disease, which requires dialysis or kidney transplant for
survival,” commented Stephen C. Glover, ZyVersa’s Co-founder,
Chairman, CEO and President. “Although substantial progress has
been made in slowing progression of DKD with introduction of ACE
inhibitors, ARBs, and most recently SGLT2 inhibitors, patients are
still progressing to end-stage renal disease. The data published in
Alternative Therapies suggest that early DKD intervention with
inflammasome inhibitors has potential to help attenuate disease
progression.”
About Inflammasome ASC Inhibitor IC
100
IC 100 is a novel humanized IgG4 monoclonal
antibody that inhibits the inflammasome adaptor protein ASC. IC 100
was designed to attenuate both initiation and perpetuation of the
inflammatory response. It does so by binding to a specific region
of the ASC component of multiple types of inflammasomes, including
NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100
binds to ASC monomers, inhibiting inflammasome formation, thereby
blocking activation of IL-1β early in the inflammatory cascade. IC
100 also binds to ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune response.
To review a white paper summarizing the mechanism of action and
preclinical data for IC 100, Click Here.
About ZyVersa Therapeutics,
Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage
specialty biopharmaceutical company leveraging advanced,
proprietary technologies to develop first-in-class drugs for
patients with renal and inflammatory diseases who have significant
unmet medical needs. The Company is currently advancing a
therapeutic development pipeline with multiple programs built
around its two proprietary technologies – Cholesterol Efflux
Mediator™ VAR 200 for treatment of kidney diseases, and
Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation
associated with numerous CNS and other inflammatory diseases. For
more information, please visit www.zyversa.com.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements contained in this press release
regarding matters that are not historical facts, are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995. These include statements
regarding management’s intentions, plans, beliefs, expectations, or
forecasts for the future, and, therefore, you are cautioned not to
place undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not
possible for ZyVersa to predict all such factors, nor can ZyVersa
assess the impact of each such factor on the business or the extent
to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Forward-looking statements included in
this press release are based on information available to ZyVersa as
of the date of this press release. ZyVersa disclaims any obligation
to update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
Corporate and IR Contact:Karen
CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave
Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024